Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced...
Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and...
Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment...
Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first subject...
Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena (Public...
Navarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase 1...
Medibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of Medibiofarma, made...
Medibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena, a public...
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.